updat model
earn speak compani
bottom line follow rel volatil week earn
rel straightforward see
much reason chang thesi either stock maintain
outperform rate target price maintain neutral
rate lower target price
bullish merck remain bullish given increas
advantag non-smal cell lung cancer nsclc look forward
see data trial renal cell carcinoma
stop earli last week due efficaci overal see merck
attract growth stori driven keytruda expect consensu
estim continu go next sever quarter merck rais
low end fy ep guidanc rang maintain
midpoint sale guidanc rang despit lose fx tailwind
expect initi provid top-line guidanc
begin year
cautiou bristol myer rough week
stock due updat nsclc file tmb high
patient well competitor updat esmo merck
trial feel neg sentiment littl strong
stage see risk/reward look attract keep
close eye upcom data readout immuno-oncolog space
assess posit think stock start deliv
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau univers toronto figur keytruda opdivo us sale breakdown indic
price month
updat model earn speak
compani second opinion
multipl factor drive upsid expect go earn
high lead stock react neg even though keytruda
sale essenti line continu see room addit
upsid compani continu roll keytruda notabl
line non-smal cell lung nsclc set well renal head
neck may potenti best-in-class data outsid
oncolog think gardasil remain underappreci like also
provid upsid acknowledg
concern compani navig januvia patent
expir believ intrigu bd possibl
team consid addit possibl separ anim health
busi anoth way gener sharehold valu even without
meaning strateg action see signific opportun merck
improv profit continu return excess cash sharehold
notabl model updat make chang above-consensu
sale forecast keytruda beyond continu expect
consensu estim increas increas sale gardasil
modestli lower sale number product outsid us
alreadi declin result revenu declin
expect ep
maintain out-performance pt tp base
blend dcf rel valuat rel
base new ep blue sky
valuat grey sky valuat risk primari risk
view poor execut commerci opportun
valuat metric
number share
 close
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
merck co inc global health care compani deliv health
solut prescript medicin market
joint ventur oper segment
anim health consum allianc
blue sky valuat base greater sale
keytruda januvia gardasil compar current base case
assumpt also model higher gross margin oper
margin base case assumpt blue sky valuat
base dcf driven wacc termin valu
grey sky valuat base lower sale
keytruda januvia gardasil compar current base case
assumpt also model lower gross margin oper
margin base assumpt grey sky valuat base
dcf driven wacc termin valu
 close
opportun speak member ir team follow
confer call gain addit clariti dynam around certain
product well bake expect go forward
summar compani answer question
 price us vs ex-u keytruda
disclos get good price eu strong os benefit
make discuss lot smoother feel pretti good price end
compani need provid valu drug get better reimburs
focu
 anyth ex-u number explain littl low
zetia vytorin see gener eros continu futur regard
currenc impact minim oppos benefit assum earlier
year simponi also see competit entrant biosimilar brand
drug growth driver
 driver gardasil perform quarter
cdc replenish paid
replenish quarter still plan end season play big
part alway bigger due back school vaccin move gender-
neutral program eu good vaccin renew growth gardasil
given men women see strength sinc product
execut jv anymor
 comment gener competit nuvar
actual benefit delay gener entri expect earli
delay launch probabl around manufactur expect normal eros curv
gener enter
 januvia/janumet one-tim item number
number clean good ex-u growth us though slow
head toward loss patent exclus
 anticip lung ramp first line ex-u like seen us
slower ex-u due slower ramp reimburs agreement
make slower
 indic key keytruda besid lung
melanoma head neck bladder three main approv ex-u besid lung
lung number one three roughli even melanoma
 rcc data esmo-io
sure esmo-io past present renal
data asco-gu februari want present data soon
 someth artifici boost adempi quarter
collabor bayer mean report sale territori eu japan
bayer pay us us sale gave us payment accru
quarter boost number somewhat
 adjuv melanoma market size
patient elig small still sizabl opportun
recent receiv chmp support februari pdufa us
 continu see tax rate benefit guidanc futur tax rate
guidanc year came need wait
guidanc commentari
 wouldnt cash kept us tax reform pass tax
oversea cash anyway
reform bring us flexibl intent bring cash back us
longer ex-u pre-reform actual
 anyth underappreci regard bridion
growth us strong fatten japan much higher
penetr rate share
summar mrk answer analyst question compani
earn confer call
 think ceo retir term busi develop
anim health busi guid compani toward potenti
disciplin commit acquir asset provid valu
chang previou strategi deal size think whether
right one fact ceo stay longer chang
strategi
 sting monotherapi impact seem limit expect
think regard pipelin approach
import rememb birth announc given
stimul inflamm pattern inject tumor respons
suggest effect keytruda alon adjunct
therapi seek improv keytruda respons gener
enthusiast inflammatori mediat sting still earli
 rcc see keytruda combo rel opdivo yervoy
top-line result first interim analysi met endpoint import
thing much treatment affect sinc efficaci extrem import
think peopl like data
 line lung cancer treatment europ keytruda stand term
penetr roll-out posit comment
see signific growth combo tripl size elig market
howev nsclc ramp slow person come
treat first time come fail drug trial way
combo consid roll-out germani exampl littl faster
due reimburs agreement compar countri
 keytruda usag tumor type us ex-u
us nsclc melanoma head neck bladder
indic europ launch monotherapi patient
greater make signific end road lung
largest tumor type europ
 recent comment state first time margin expans
meaning color
happen time oncolog drive margin expans relat actual
number time period right thing us give guidanc
continu give annual guidanc current focus drive margin
expans make right kind invest end
 sell anim health busi creat growth futur
kind offer would need sell part portfolio
alway activ evalu portfolio share market excit
around anim health howev believ run busi well intern
compar competitor believ continu run well activ
review portfolio look market develop regard continu
evalu entir portfolio on-going basi alway
 busi develop prioriti consid growth emphas
due risk manag
solid growth right never comfort growth
pipelin could realli never strong enough question de-risk
 rank term compani prioriti
molecul look pretti good tri establish dose
schedul would combin look promis us may possibl
develop go forward explicit decis right mostli
want make sure peopl awar combo potenti present
 mention busi develop six time prioriti prepar
comment area think ad pipelin
comment
everybodi recogn biopharma compani alway case
busi develop materi contribut expans us major
molecul acquir extern fundament interest best
scienc opportun patient care
 wake rcc see meaning opportun improv data
tki
data set extrem interest everi tki slightli differ
characterist success lenvima promis enthusiast
 opportun adjuv non-adjuv tnbc set
close dmc review hope happen hard predict data
anyth add tripl neg breast cancer treatment would
welcom look forward see data
 given latest updat os affect
think keytruda
much influenc singl studi like rel
modest info weve done quit larg studi compar tmb vs inflammatori
signatur mutat influenc respons rate import clear
immun respons import studi continu studi
dont see tmb test select patient keytruda monotherapi
 state busi develop critic compani growth
think us drug price reform affect would
affect
long find product one compet good
reimburs wouldnt want late entrant price
pressur someth would similar exist drug
 think gardasil eu also male
expect lumpi short term growth signific growth opportun time
us china even eu see big growth opportun countri look
australia given gardasil men differ countri put differ
program term vaccin peopl begin understand need vaccin
men women
 capit spend increas accord guidanc chanc demand
outstrip suppli especi vaccin
capac expand around broader vaccin portfolio key growth area
like gardasil keytruda anim health plan significantli increas
vaccin suppli think demand continu grow
unpreced increas vaccin doubl last year alon relat
polici chang drive growth look specif product suppli
meaning increas gardasil suppli abil increas suppli
meaning go forward need suppli
 comment propos presid around part price reform given
potenti impact keytruda
lot talk need see detail around would
implement agre need get patient meaning access part
drug realli earli comment continu interact washington
issu
 color margin expans consensu quarter
key messag expect meaning margin expans due mix
product use invest drive growth comment vs consensu
 power power increas color around
ensur result good possibl focu us
dont see data would chang studi simpli look everyth everyon
tri improv studi alway go exactli
right well best
 us sale medicar medicar part
dont break segment growth come differ area
much bigger medicar medicaid lot medicar medicaid data
retroact well comment exact number breakdown
 drive anim health growth
see busi driven innov pipelin synergi human
health drive growth long term portfolio strong
compani data credit suiss estim consensu streetaccount bloomberg professionaltm
m-m-r ii net pf dilut charl martineau univers toronto
expens yoy rate rate item acquisition- divestiture-rel charg relat format collabor relat termin collabor agreement viralyt decreas increas incom tax benefit increas net guidancefeb charl martineau univers toronto
profit incom total incom provis incom non-controlling averag per analysisgross margin incom rate rate salesyear/year per charl martineau univers toronto
revenu revenu m-m-r ii women medicin women implanon specialti hospit acut hcv regimen letermovir charl martineau univers toronto
price month
updat model earn speak
compani second opinion
solid quarter cautiou go forward due evolv immuno-
oncolog dynam deliv solid earn well
cs consensu estim key product like opdivo yervoy
drive beat eliqui came cs
consensu estim due impact donut hole
inventori fluctuat us one-tim price
adjust outsid us question revolv
around next sever quarter competit pressur immuno-
oncolog space mount wait addit data releas
could turn stori around updat model earn slightli
modifi estim sever product notabl opdivo yervoy
lead ep chang
lower target price
maintain neutral rate main risk view
surprisingli strong commerci execut key market product
surpris posit neg import clinic trial especi lung
kidney cancer
valuat target price blend dcf
rel valuat blue sky valuat grey
sky valuat pleas let us know would like updat
valuat metric
number share
 close
price oct rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
opportun speak member ir team follow
confer call gain addit clariti dynam around certain
product well bake expect go forward
summar compani answer question
 besid adjuv melanoma would drive ex-u sale
stabl busi lung contract next year gain ex-
us lung revenu gradual eros come soon line melanoma
renal head neck colorect refractori possibl growth driver
checkmat readout end posit patient
checkmat line cis-inelig popul line combo checkmat
sclc mainten think differenti respond initi
therapi go studi benefit chemo usual temporari
 impact one-tim item quarter
eliqui impact coverag gap pronounc
lowest true histor
also charg relat inventori us also ex-u
impact due ad discount gave regard prior sale
 gross margin guidanc beyond
fx tailwind moder mix eliqui i-o stabil gm
guidanc key growth profil opdivo grow base
current indic trial read inform profil differ
sprycel gm eliqui opdivo compani averag yervoy
even higher orencia typic biolog without royalti
 tax guidanc beyond
one-tim revers prior period adjust drove lower tax
rate still full year see long term margin improv tax
rate compani fulli implement tax reform intern multi-year process
relat manufactur network long term tax rate go reform
last time could time
 detail net price opdivo yervoy ex-u
roughli eu compar us
 time initi pivot studi
priorit grow busi organ commit lung studi
nektar yet three indic far enter registr
trial data would like move quick possibl
 charg ex-u cash whether bring correct keep
ex-u
upon sign tax reform took charg year
pay tax govern perpetu tax ex-u profit
cash us ex-u part tax profit ex-u cash
need certain level cash foreign oper support also
summar bmi answer analyst question compani
earn confer call
 rcc increasingli fragment market confid
strong base book rcc share opdivo low dose
yervoy continu standard care us demonstr
patient qualiti life improv well toler consid know
competit profil expect continu need see mrk full
data give comment market feel good rcc
 view data relat yervoy esmo
comment data target us combin opdivo
yervoy seen better pro-bodi develop
preferenti get tumor modul immun events/accentu anti-tumor event
phase expect readout import
target us look forward present data next year
 feel like back came
year ago look less less like role lung
hedg bet suppos import growth becom
import grow futur read buy-back done
save
strategi broaden clinic trial design reflect
broader approach i-o continu think busi develop
demonstr fairli balanc capit alloc strategi
 priorit tmb
introduc measur tmb number differ studi
attempt collect look forward see interact number
biomark hope give us opportun data till next year
 confirm dose
target cynokinas without jak side effect take time
understand fulli havent disclos dose yet competit reason develop
psoriasi psoriat arthriti lupu work
 sort hazard ratio think show non-squam get
doctor continu use opdivo also beyond opdivo growth
today get guidanc
look forward see chemo result event driven predict readout
hazard ratio believ patient necessarili care care
surviv durat depth durabl treatment import feel pretti good
year see opdivo growth base current indic give
post guidanc januari feel good busi meantim
 opdivo lung see market evolv
market share stabl roughli seen continu declin
elig patient gradual outsid us due us
elig still expect level
 result chang view tmb predict biomark
high tmb respons rate clearli show better odd surviv patient
opinion reason didnt look tmb low popul initi protect integr
trial eu regul overal surviv trend patient treat
opdivo yervoy high tmb clearli predict subgroup patient tmb
prognost well certain degre benefit better high tmb import
rememb earli stage still look understand tmb
 opdivo sale breakdown today chang year
current lung renal melanoma ex-u see
differ lung renal melanoma dynam time us
larger renal cell due frontlin adjuv melanoma launch outsid
us continu diversif us percent lung cancer ex-u
decreas get busi adjuv melanoma
 give color chang sampl size
regard criteria discontinu consist
trial rate rate accrual ad hundr patient could
increas option look biomark thought would increas
possibl
 plan submit delay comment
chang
dont comment interact regul firm commun
encourag see altern dose data safeti studi
import implic commerci promot see doc adopt
dont anticip wholesal shift registr intent option
doctor import event driven number event occur wait
look forward compar tki share data asap get take time
 eliqui much lower think drive warfarin use
warfarin new share us overal ex-u util constraint
us familiar price continu belief take share
 busi develop big small
busi develop line previou statement current strategi
 thought drug price given hh propos today regard part
earli comment drug price
sell non-operating incom countdilut charl martineau univers toronto
profit sell net incom allianc licens total incom forma pre-tax provis incom interest incom dilut averag cont op start analysisgross margin promot continu charl martineau univers toronto
 product product ii pipelin product compani charl martineau univers toronto
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
